Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 31, 2018
Ceasing to be a substantial holder
Dec 18, 2018
2018 Year-end Business Update
Dec 17, 2018
Larry Glass to retire as a director and continue as CSO
Nov 02, 2018
Presentation at AusBiotech Invest and Partnering 2018
Oct 31, 2018
Appendix 4C - quarterly
Oct 26, 2018
Trofinetide ex-North America exclusive negotiation period
Oct 17, 2018
Neuren and ACADIA hold Rett syndrome SAB meeting
Oct 01, 2018
Change of Director's Interest Notice
Sep 21, 2018
FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
Sep 06, 2018
Investor presentation, 6 September 2018
1
2
3
4
Next
